CompletedPhase 2NCT00073983
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Studying Chondrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Principal Investigator
- Shreyaskumar R. Patel, MDSarcoma Alliance for Research through Collaboration
- Intervention
- filgrastim(biological)
- Enrollment
- 54 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2006 – 2010
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00073983 on ClinicalTrials.govOther trials for Chondrosarcoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07360964Clear Cell Chondrosarcoma in ItalyIstituto Ortopedico Rizzoli
- RECRUITINGNCT07315542Diagnostic and Therapeutic Targets in Cartilaginous TumoursSt. Anne's University Hospital Brno, Czech Republic
- RECRUITINGEARLY PHASE1NCT06645808PET-imaging of Two Vartumabs in Patients With Solid TumorsVar2 Pharmaceuticals
- RECRUITINGPHASE3NCT06127407Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment RegimenServier Bio-Innovation LLC
- RECRUITINGNCT06486506Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic ResultsCostantino Errani
- RECRUITINGPHASE2NCT06176989Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNational Cancer Institute (NCI)
- RECRUITINGNANCT06387485A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative PlanningRicoh USA, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05836571Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaNational Cancer Institute LAO